Laurus Labs conducted their earnings con-call today at 11:00 am
Here are the key highlights ππ
@unseenvalue @drprashantmish6 @punitbansal14 @shrutiahuja110 @SwarnashishC
#concall
Here are the key highlights ππ
@unseenvalue @drprashantmish6 @punitbansal14 @shrutiahuja110 @SwarnashishC
#concall
Business Updates:
β’ Contributor for this year was the robust product basket.
β’ Formulation contribution of 39%.
β’ See product filing in image
β’ Continue investing in infrastructure.
β’ De-bottle-necking the plant continuous to remain online.
β’ Contributor for this year was the robust product basket.
β’ Formulation contribution of 39%.
β’ See product filing in image
β’ Continue investing in infrastructure.
β’ De-bottle-necking the plant continuous to remain online.
β’ Expanding capacities in key API.
β’ See the segment revenue breakup in the image.
β’ Dedicated a special plant location for CRAMS Facility.
β’ Richcore will be named as Lauruas Bio and acquired 100% in Richcore
β’ See the segment revenue breakup in the image.
β’ Dedicated a special plant location for CRAMS Facility.
β’ Richcore will be named as Lauruas Bio and acquired 100% in Richcore
TLE to TLE transaction
β’ Majority of the sales coming from TLD.
β’ However company has more molecules filed in TLE which make more growth available in TLE segment
β’ Majority of the sales coming from TLD.
β’ However company has more molecules filed in TLE which make more growth available in TLE segment
β’ ARV margins- Gross margins was less in Q3 due to delay of of export incentives. However this quarter margins remain on line.
Capacity:
β’ Currently company is at optimum utilization and de-bottlenecking of the plant will be finished in Q4.
Capacity:
β’ Currently company is at optimum utilization and de-bottlenecking of the plant will be finished in Q4.
β’ There are 8 formulation player active who have filed for Doltagrovate molecule while there are no player who is WHO certified for the API division.
HIV:
β’ Doubling the segment is impossible as the patients in the disease are not that higher.
β’ Growth in HIV will come from demand moving from weak players to strong players.
β’ Doubling the segment is impossible as the patients in the disease are not that higher.
β’ Growth in HIV will come from demand moving from weak players to strong players.
Diabetic and Cardiovascular
β’ Strong product basket in Diabetic, while Cardiovascular will be another growth driver.
β’ There are not much development left in ARV segment for Laurus, hence in future major growth driver non ARV.
β’ After 3-5 year, growth driver will be Laurus Bio
β’ Strong product basket in Diabetic, while Cardiovascular will be another growth driver.
β’ There are not much development left in ARV segment for Laurus, hence in future major growth driver non ARV.
β’ After 3-5 year, growth driver will be Laurus Bio
Investment in Laurus Bio
β’ Co. don't see any challenges to invest over there
β’ Bio is high margin business and is expected to deliver good cash flow for the business. Hence mgmt expect most of the investment to be internally funded.
β’ Not much of CAPEX is allocated now to Bio.
β’ Co. don't see any challenges to invest over there
β’ Bio is high margin business and is expected to deliver good cash flow for the business. Hence mgmt expect most of the investment to be internally funded.
β’ Not much of CAPEX is allocated now to Bio.
Nutraceuticals and Cosmoceuticals
β’ It was added in CDMO product. As it also commodity business company is not much in the business but there are tie ups with big customer.
β’ It was added in CDMO product. As it also commodity business company is not much in the business but there are tie ups with big customer.
Long Active Injectables
β’ Co. is watching ARV business since past many years, hence any new disruption will be in close eyes of Laurus.
β’ Injectables is currently not signed by WHO and and company don't expect it till 2025
β’ Co. have molecules in the pipeline for injectables.
β’ Co. is watching ARV business since past many years, hence any new disruption will be in close eyes of Laurus.
β’ Injectables is currently not signed by WHO and and company don't expect it till 2025
β’ Co. have molecules in the pipeline for injectables.
For more stock market discussion do join our Telegram Channel
t.me/thetycoonmindsβ¦
t.me/thetycoonmindsβ¦
β’ β’ β’
Missing some Tweet in this thread? You can try to
force a refresh
γ
